EW Edwards Lifesciences Corp

Price (delayed)

$110.6

Market cap

$69.05B

P/E Ratio

46.67

Dividend/share

N/A

EPS

$2.37

Enterprise value

$68.23B

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of ...

Highlights
The company's EPS has surged by 87% YoY
The net income has soared by 86% YoY

Key stats

What are the main financial stats of EW
Market
Shares outstanding
624.33M
Market cap
$69.05B
Enterprise value
$68.23B
Valuations
Price to earnings (P/E)
46.67
Price to book (P/B)
12.44
Price to sales (P/S)
13.54
EV/EBIT
40.2
EV/EBITDA
36.67
EV/Sales
13.39
Earnings
Revenue
$5.09B
EBIT
$1.7B
EBITDA
$1.86B
Free cash flow
$1.41B
Per share
EPS
$2.37
Free cash flow per share
$2.26
Book value per share
$8.89
Revenue per share
$8.17
TBVPS
$10.69
Balance sheet
Total assets
$8.16B
Total liabilities
$2.62B
Debt
$684.1M
Equity
$5.54B
Working capital
$2.55B
Liquidity
Debt to equity
0.12
Current ratio
3.64
Quick ratio
2.54
Net debt/EBITDA
-0.44
Margins
EBITDA margin
36.5%
Gross margin
75.7%
Net margin
29%
Operating margin
30.7%
Efficiency
Return on assets
19.5%
Return on equity
29.7%
Return on invested capital
37.1%
Return on capital employed
23.6%
Return on sales
33.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EW stock price

How has the Edwards Lifesciences stock price performed over time
Intraday
-1.82%
1 week
-6.48%
1 month
-13.98%
1 year
29.33%
YTD
-14.63%
QTD
-14.63%

Financial performance

How have Edwards Lifesciences's revenue and profit performed over time
Revenue
$5.09B
Gross profit
$3.86B
Operating income
$1.57B
Net income
$1.48B
Gross margin
75.7%
Net margin
29%
The net income has soared by 86% YoY
The operating income has soared by 85% YoY and by 2.8% from the previous quarter
The net margin has soared by 59% YoY but it has contracted by 2.4% from the previous quarter
The company's operating margin has surged by 58% YoY

Growth

What is Edwards Lifesciences's growth rate over time

Valuation

What is Edwards Lifesciences stock price valuation
P/E
46.67
P/B
12.44
P/S
13.54
EV/EBIT
40.2
EV/EBITDA
36.67
EV/Sales
13.39
The company's EPS has surged by 87% YoY
The price to earnings (P/E) is 16% lower than the last 4 quarters average of 55.8 and 3.8% lower than the 5-year quarterly average of 48.5
The equity has grown by 32% year-on-year and by 8% since the previous quarter
The stock's price to book (P/B) is 18% more than its 5-year quarterly average of 10.5
The P/S is 37% above the 5-year quarterly average of 9.9 and 5% above the last 4 quarters average of 12.9
EW's revenue is up by 17% year-on-year and by 3.4% since the previous quarter

Efficiency

How efficient is Edwards Lifesciences business performance
The company's return on sales has surged by 62% YoY
EW's return on assets has surged by 59% year-on-year but it is down by 3.5% since the previous quarter
The company's return on invested capital has surged by 59% YoY but it fell by 2.6% QoQ
Edwards Lifesciences's return on equity has surged by 51% YoY but it has decreased by 6% QoQ

Dividends

What is EW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EW.

Financial health

How did Edwards Lifesciences financials performed over time
The total assets is up by 20% year-on-year and by 7% since the previous quarter
EW's quick ratio is up by 9% year-on-year
The debt is 88% less than the equity
The equity has grown by 32% year-on-year and by 8% since the previous quarter
The company's debt to equity fell by 25% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.